Lifestyle

HanmiPharm’s ‘Epe’ Sells Out Initial 10 Billion Won Shipment… Positive Sign for New Obesity Drug’s Success [Bio Spotlight]

KIM JI-WAN
2026-11-22 08:31:03
[Edaily Reporter KIM JI-WAN ] Amid a sharp decline in the domestic stock market on the 20th, HanmiPharm rose more than 6% on news of the initial success of its domestically developed obesity treatment, “Epe.” HK inno.N Corporation closed higher on expectations that its gastroesophageal reflux disease (GERD) treatment, “K-Cap,” will receive approval from the U.S. FDA in January of next year. BIONEER CORPORATION raised expectations for a global technology transfer, led by its proprietary RNA interference (RNAi) platform.

(Graphic: ChatGPT)


On this day, the pharmaceutical sector fell 1.34% and the life sciences sector dropped 2.50%. Within the pharmaceutical sector, only 18 of the 161 listed stocks rose, while a whopping 131 closed lower. In the life sciences sector, 68 out of 93 stocks saw their share prices fall compared to the previous day.

HanmiPharm Rises on Complete Sell-Out of Initial ‘Epe’ Shipment
HanmiPharm(128940)’s stock surged on news that the company had sold out its initial supply of the domestically developed obesity treatment
“Epe
,” worth 10 billion won, ahead of schedule. The rapid depletion of the initial supply following the start of domestic prescriptions is seen as driving the stock price higher, fueled by expectations of full-scale sales growth.

According to KG Zeroin MP Doctor, HanmiPharm closed at 449,000 won, up 27,000 won (6.40%) from the previous trading day. This trend stood in contrast to the KOSPI and KOSDAQ indices, which plunged by more than 5% during the session.

The key driver behind the stock price rise is optimism surrounding the commercialization of Epe. Epe, which began domestic prescribing on the 29th of last month, sold out its initial inventory—valued at approximately 10 billion won based on the supply price—in just two business weeks. Analysts attribute this strong initial demand to a pricing strategy that set the supply price for the first four weeks at 129,800 won, roughly half the price of its competitor, Mounjaro.

Recently released long-term clinical results are also positive. On the 16th, HanmiPharm presented the 64-week treatment results from Epe’s Phase 3 clinical trial—conducted on 448 obese and overweight adults in Korea—at the American Society for Metabolic and Bariatric Surgery (ASMBS) conference. The average weight loss rate was 10.56%, an increase of 0.81 percentage points from the previous 40-week result of 9.75%.

Expectations for the development of follow-up obesity treatments also contributed to the stock price rise. KB Securities maintained its “Buy” rating and target price of 650,000 won for HanmiPharm on the same day. This represents an upside potential of approximately 54% compared to the previous day’s closing price.

HanmiPharm’s first domestically developed glucagon-like peptide (GLP)-1 class obesity drug, “Epe” (Photo: HanmiPharm)


Shin Ji-hoon, an analyst at KB Securities, predicted that the likelihood of a technology transfer will increase as the U.S. Phase 2 clinical trial for the triple-action obesity treatment Zantrutide (HM15275) concludes in the first half of next year. HM17321, an obesity treatment candidate licensed to Roche, is also set to complete its Phase 1 clinical trial in the first half of next year.

HanmiPharm plans to build on its initial market foothold to expand sales of Epe. The company plans to expand distribution to hospitals, clinics, and pharmacies nationwide in January of next year and gradually increase production capacity.

A HanmiPharm official stated, “In the medium to long term, we aim to increase Epe’s sales to 200 billion won.”
HK inno.N Corporation: Optimism Over ‘K-Cap’ U.S. Launch
HK inno.N Corporation(195940)closed higher on
optimism
surrounding the
U
.S. market
launch
of
“K-Cap
,” a treatment for gastroesophageal reflux disease. Expectations for improved earnings are growing as a decision on approval by the U.S. Food and Drug Administration (FDA) is expected in January, coinciding with a recovery in domestic sales.

On this day, HK inno.N Corporation closed at 38,450 won, up 850 won (2.26%) from the previous trading day.

The rise in the stock price is driven by expectations surrounding K-Cap’s entry into the U.S. market. KB Securities maintained its “Buy” rating and a target price of 70,000 won for HK inno.N Corporation today. It projected next year’s revenue to reach 1.1204 trillion won—a 4.4% increase from this year—and operating profit to rise 22.8% to 159.2 billion won.

In particular, K-Cap’s entry into the U.S. market was cited as a key factor in the revaluation of the company’s enterprise value. If FDA approval is obtained in January of next year, the company is expected to generate revenue from milestone payments and sales royalties. KB Securities projected that K-Cap’s U.S. sales will reach $400 million by 2031.

HK inno.N Corporation’s new drug for gastroesophageal reflux disease, “K-Cap” (active ingredient: tegoprazan), has received marketing approval in Chile under the brand name “K-Cap.” (Courtesy of HK inno.N Corporation)


The U.S. market environment is also favorable. “Boquezna,” a treatment in the same class that was launched earlier, recorded sales of $84.7 million in the third quarter of this year, marking a 71% year-over-year increase. Analysts suggest that as the existing product pioneers the market, the barriers to entry for K-Cap may also be lowered.

A recovery in domestic performance is also anticipated. While K-Cap’s third-quarter outpatient prescription volume reached 65.4 billion won—a 16.5% increase year-over-year—revenue decreased by 15% due to the impact of drug price rebates and inventory adjustments. The securities industry expects that as these temporary factors subside, increased prescriptions will lead to revenue growth starting next year.

Shin Ji-hoon, an analyst at KB Securities, stated, “It is positive that existing treatments have already gone through a trial-and-error process in the U.S. market, thereby raising awareness among healthcare professionals and streamlining insurance coverage procedures,” adding, “Since K-Cap is being launched in an environment where a market foundation has already been established, it will have an advantage in its initial market entry.”
BIONEER CORPORATION Seeks Global Technology Transfer by Highlighting Its RNA Drug Platform
BIONEER CORPORATION(064550)explored potential collaborations with global pharmaceutical companies by showcasing its proprietary RNA interference (RNAi) technology at Europe’s largest pharmaceutical and biotech partnering event.

BIONEER CORPORATION announced that it participated in BIO-Europe 2026, recently held in Cologne, Germany, and conducted about 20 one-on-one meetings with global pharmaceutical companies and major European medical institutions. BIONEER CORPORATION’s stock price rose 1,070 won (16.54%) from the previous trading day to close at 7,540 won.

At the event, BIONEER CORPORATION introduced its proprietary semi-RNA platform. Semi-RNA is a technology that delivers short interfering RNA (siRNA) in the form of nanoparticles to specific tissues. It is designed to reduce systemic exposure through local administration.

New Cosmerna packaging. (Courtesy of BIONEER CORPORATION)


BIONEER CORPORATION has already commercialized “Cosmerna,” a hair loss treatment cosmetic that utilizes this technology. Building on this, the company is also pursuing the development of a next-generation hair loss treatment drug that acts directly on hair follicles. The development goal is to reduce hormone-related systemic side effects that can occur with existing oral hair loss treatments.

The fibrosis treatment candidate “SRN001” has also emerged as a key topic for collaboration discussions. SRN001 is a candidate that inhibits amphiregulin (AREG), a protein involved in fibrosis, and is currently undergoing a Phase 1b repeated-dose clinical trial. The company plans to finalize technology transfer negotiations once clinical data is secured.

In the molecular diagnostics business, the company also held discussions with three European medical institutions. It introduced the point-of-care diagnostic device “IRON-qPCR” and the automated system “ExiStation FA 96,” and discussed the possibility of conducting local clinical evaluations.

A BIONEER CORPORATION official stated, “The focus of global RNAi drug development is shifting from liver diseases to extrahepatic tissues such as fat, muscle, lungs, and skin,” adding, “We will continue follow-up discussions with the partners we met at this event and strive to achieve tangible results based on clinical data and molecular diagnostics evaluation results.”

Economy

Corporation

IT·Science

Economy

Securities Tokenization: How Will Settlement Change?

If you sell stocks on Monday, the sale will appear immediately in your brokerage account. Assuming there are no market holidays in between, you can transfer the proceeds from the sale to your bank acc…
2026-11-22 05:00:03

Corporation

HanmiPharm’s ‘Epe’ Sells Out Initial 10 Billion Won Shipment… Positive Sign for New Obesity Drug’s Success [Bio Spotlight]

Amid a sharp decline in the domestic stock market on the 20th, HanmiPharm rose more than 6% on news of the initial success of its domestically developed obesity treatment, “Epe.” HK inno.N Corporation…
2026-11-22 08:31:03

IT·Science

Hanmi’s Obesity Drug Epe Sells Out in Record Time [K-Bio Pulse]

Despite a sharp decline in South Korea’s stock market on November 20, Hanmi Pharmaceutical rose more than 6% on strong initial demand for its domestically developed obesity drug, Epe. HK inno.N also c…
2026-11-22 08:31:02